DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) General Information

Description

Molecular testing PROGENSA PCA3 assay diagnostic application. The asset develops diagnostic application for the detection of prostate cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Quebec
  • Canada
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Hologic
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Quebec
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)‘s full profile, request access.

Request a free trial

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)‘s full profile, request access.

Request a free trial

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) FAQs

  • Where is DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) headquartered?

    DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) is headquartered in Canada.

  • What industry is DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) in?

    DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)’s primary industry is Buildings and Property.

  • Is DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) a private or public company?

    DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) is a Private company.

  • What is the current valuation of DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)?

    The current valuation of DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) is .

  • What is DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)’s current revenue?

    The current revenue for DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) is .

  • Who are DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)’s investors?

    DiagnoCure has invested in DiagnoCure (PCA3 Prostate Cancer Biomarker Assets).

  • When was DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) acquired?

    DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) was acquired on 17-Feb-2016.

  • Who acquired DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)?

    DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) was acquired by Hologic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »